PL1934243T3 - Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych - Google Patents

Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Info

Publication number
PL1934243T3
PL1934243T3 PL06803140T PL06803140T PL1934243T3 PL 1934243 T3 PL1934243 T3 PL 1934243T3 PL 06803140 T PL06803140 T PL 06803140T PL 06803140 T PL06803140 T PL 06803140T PL 1934243 T3 PL1934243 T3 PL 1934243T3
Authority
PL
Poland
Prior art keywords
formula
compound
preparation
ring
closing metathesis
Prior art date
Application number
PL06803140T
Other languages
English (en)
Inventor
Chutian Shu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL1934243T3 publication Critical patent/PL1934243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL06803140T 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych PL1934243T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71553405P 2005-09-09 2005-09-09
EP06803140A EP1934243B1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides
PCT/US2006/034921 WO2007030656A1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides

Publications (1)

Publication Number Publication Date
PL1934243T3 true PL1934243T3 (pl) 2011-10-31

Family

ID=37549189

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06803140T PL1934243T3 (pl) 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Country Status (9)

Country Link
US (1) US7951773B2 (pl)
EP (1) EP1934243B1 (pl)
JP (1) JP5190364B2 (pl)
AT (1) ATE510846T1 (pl)
CA (1) CA2621360C (pl)
DK (1) DK1934243T3 (pl)
ES (1) ES2364426T3 (pl)
PL (1) PL1934243T3 (pl)
WO (1) WO2007030656A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
JP5517614B2 (ja) 2006-07-13 2014-06-11 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての４−アミノ−４−オキソブタノイルペプチド類
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
WO2009073780A1 (en) * 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
TW200936131A (en) 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20110263844A1 (en) * 2008-05-09 2011-10-27 Boehringer Ingelheim International Gmbh method for preparing macrocycles
EP2323981B1 (en) * 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR101762842B1 (ko) 2008-12-10 2017-08-04 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 유용한 신규한 4-아미노-4-옥소부타노일 펩티드
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA201490892A1 (ru) * 2011-10-28 2014-08-29 Янссен Фармасьютикалз, Инк. Усовершенствованный способ получения промежуточного соединения макроциклического ингибитора tmc 435 протеазы
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
SG11201507469RA (en) 2013-03-14 2015-10-29 Achillion Pharmaceuticals Inc Processes for producing sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO1999000397A1 (en) 1997-06-27 1999-01-07 Ciba Specialty Chemicals Holding Inc. Ruthenium and osmium catalysts
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
KR20060008877A (ko) * 2003-04-10 2006-01-27 베링거 인겔하임 인터내셔날 게엠베하 루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법
EP1615947A2 (en) 2003-04-10 2006-01-18 Boehringer Ingelheim International GmbH Process for preparing macrocyclic compounds
WO2005028501A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus

Also Published As

Publication number Publication date
DK1934243T3 (da) 2011-09-05
JP2009509933A (ja) 2009-03-12
US7951773B2 (en) 2011-05-31
CA2621360C (en) 2013-12-24
EP1934243B1 (en) 2011-05-25
CA2621360A1 (en) 2007-03-15
WO2007030656A1 (en) 2007-03-15
WO2007030656A8 (en) 2007-07-05
US20080242835A1 (en) 2008-10-02
ATE510846T1 (de) 2011-06-15
ES2364426T3 (es) 2011-09-02
JP5190364B2 (ja) 2013-04-24
EP1934243A1 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
PL1934243T3 (pl) Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
WO2004092203A3 (en) Process for preparing macrocyclic compounds
WO2006096652A3 (en) Process for preparing macrocyclic compounds
IL178080A0 (en) Process for preparing macrocyclic compounds
CN102140100B (zh) 高效抑制丙型肝炎病毒的多环化合物及其制备方法和用途
PE20060607A1 (es) Derivados de indol tetraciclicos como agentes antivirales
RS50815B (sr) Kondenzovana heterotetraciklična jedinjenja i njihova upotreba kao inhibitora hcv polimeraza
SG163613A1 (en) Macrocyclic inhibitors of hepatitis c virus
NZ588179A (en) Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety
NZ586232A (en) HCV protease inhibitors comprising a functionalised proline derivative
WO2008057873A3 (en) Inhibitors of hepatitis c virus
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
TW200801044A (en) Macrocylic inhibitors of hepatitis C virus
SG164376A1 (en) Hcv ns3 protease inhibitors
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
Wang et al. N-Bromosuccinimide as an oxidant for the transition-metal-free synthesis of 2-aminobenzoxazoles from benzoxazoles and secondary amines
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
MX2012002958A (es) Compuestos antivirales heterociclicos.
TH80266B (th) อนุพันธ์นิวคลีโอไซด์สำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ c
TH73866A (th) วิธีการเตรียมอนุพันธ์ของ 7-(2'-ซับสติติว-เบตา-ไรโบฟูราโนซิล)-4-(NR2R3)-5-(ซับสติติว เอธิน-1-อิล)ไพร์โรโล[2,3-d]ไพริมิดีน